查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012856

生技药品安全检测市场：依产品类型、检测类型、应用和最终用户划分－2026-2032年全球市场预测

Biologics Safety Testing Market by Product Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生技药品安全测试市场价值将达到 73 亿美元，到 2026 年将成长至 82.9 亿美元，到 2032 年将达到 199.2 亿美元，复合年增长率为 15.41%。

主要市场统计数据
基准年 2025 73亿美元
预计年份：2026年 82.9亿美元
预测年份 2032 199.2亿美元
复合年增长率 (%) 15.41%

生物製药安全检测重点、监管预期及对实验室和生产商营运影响的策略指南

在目前的生技药品安全检测领域，科学严谨性、监管理解和实际应用三者必须系统性地融合。实验室机构、受託研究机构(CRO) 和生技药品研发公司必须调整其检测策略，以满足不断变化的产品品质、病患安全和供应链韧性方面的期望。本入门指南概述了相关人员在优先考虑对检测平台、验证流程和资料完整性实践进行投资时应考虑的关键方面。

技术创新、监管协调和不断发展的服务模式如何重塑生物製药安全测试的实践和营运重点。

目前生物製药安全检测正经历着一场变革，其驱动力来自治疗方法的多样化、分析技术的进步以及监管重点的转变。基因治疗和病毒载体细胞治疗等新型疗法的出现，催生了新的分析终点和验证挑战，迫使实验室拓展技术能力并投资开发正交检测方法。同时，次世代定序、数位PCR和高灵敏度免疫检测能够更早、更精确地检测污染物和杂质，这有助于降低风险，但也需要建立先进的专业知识和完善的品质系统。

由于关税调整影响生技药品检测设备、试剂和服务的持续供应，因此需要审查供应链弹性策略和采购结构。

2025年，关税调整将对生技药品安全测试相关利害关係人相关人员实际影响，进而影响筹资策略、供应链和成本结构规划。为降低跨境贸易摩擦带来的风险，关税措施促使各组织更加重视供应商多角化和国内能力建设。因此，采购团队正在重新评估关键仪器和重要试剂的长期采购关係，而供应链和品管经理则在探索其他认证途径，以确保测试的连续性。

详细的細項分析揭示了产品类型、测试方法、应用领域和最终用户类型如何造成不同的测试优先顺序和能力要求。

以细分市场为中心的洞察揭示了每种产品类型、检测方式、应用领域和最终用户类型的不同驱动因素和决策标准。在考虑产品类型细分时，相关人员会评估仪器性能特征、试剂和试剂盒特异性以及支持法规遵循和检测方法开发的服务价值提案之间的相互关係。仪器的评估指标包括灵敏度、处理能力和对新检测方法的适应性。试剂和试剂盒的评估指标包括批间一致性、文件记录和供应扩充性。服务的评估指标包括技术深度、结果出具速度和合规记录。

影响美洲、欧洲、中东和非洲以及亚太地区生物製药安全测试投资、监管合规策略和产能决策的区域趋势。

区域趋势对生物製药安全测试方法、基础设施投资和监管合规性有显着影响。在美洲，完善的法律规范与充满活力的创新生态系统并存，后者支援尖端分析技术的快速应用。该地区高度重视严格的方法验证、数据完整性实践以及将测试融入快速开发流程。因此，美洲的领导企业优先投资于能够提升处理能力、支持监管申报以及维持供应链稳健性的项目。

技术领先、一体化服务交付和战略伙伴关係如何定义生物製药安全测试服务和解决方案的竞争优势。

生物製药安全检测领域的竞争优势取决于技术领先地位、一体化服务以及卓越的品质保证记录的整合。主要企业凭藉检验的高灵敏度和高重现性平台脱颖而出，并辅以全面的文檔和认证的品质系统。对新兴检测方式分析方法研发的投入以及对验证方法的发表，进一步巩固了其技术领先地位，这些检验方法展现了科学的严谨性和对法规的深刻理解。

为领导者提供切实可行的操作和策略措施，以增强生物製品检测的分析稳健性、供应链韧性以及人力和数位能力。

产业领导企业应制定多管齐下的行动计划，兼顾短期营运韧性和长期能力发展。优先投资于正交测试能力和稳健的方法验证框架，以确保分析冗余性和监管合法性。此类投资不仅能降低未被发现的品质问题风险，还能提高监管检查期间产品放行决定的可信度。

采用混合方法研究途径，结合一手访谈、技术文献整合、监管指南检讨和情境分析，得出实用见解。

本分析的调查方法融合了访谈、技术文献综述、监管指南和跨产业标竿分析，以确保全面观点。访谈内容包括与实验室经理、品质经理、采购负责人以及在生物製品分析检测方面具有实务经验的专家进行结构化对话。这些讨论聚焦于引入新检测方法或扩展检测能力时所面临的实际限制、验证流程和操作权衡。

整合作为结论：将科学进步、监管压力和营运韧性联繫起来，以确定生技药品。

生技药品的安全性检测处于科学创新、监管要求和营运实施的交汇点，其有效管理对于保护患者和维护产品完整性至关重要。所有检测方式中灵敏度更高、特异性更强、速度更快的检测方法的需求日益增长，正在重塑检查室的投资和服务模式。同时，监管机构对表征和出货前检测的要求也凸显了严格验证和可追溯资料管理实务的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生技药品安全检测市场：依产品类型划分

  • 装置
  • 试剂和试剂盒
  • 服务

第九章生技药品市场安全性检测 检测类型

  • 检测外来性微生物
  • 微生物附着量测试
  • 细胞株的鑑定与表征
  • 内毒素试验
  • 霉浆菌检测
  • 残留宿主细胞蛋白（HCP）检测
  • 无菌测试

第十章：生技药品安全侦测市场：依应用领域划分

  • 基因治疗
  • 单株抗体的生产
  • 重组蛋白疗法
  • 干细胞研究
  • 组织工程
  • 疫苗研发

第十一章：生技药品安全检测市场：依最终用户划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 製药和生物技术公司

第十二章：生技药品安全检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：生技药品安全侦测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：生技药品安全检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国生技药品安全检测市场

第十六章：中国生技药品安全检测市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Associates of Cape Cod, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Clean Biologics SAS
  • Cytiva Europe GmbH
  • Danaher Corporation
  • Eurofins Scientific SE
  • FUJIFILM Corporation
  • GenScript Biotech Corporation
  • Intertek Group plc
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Microcoat Biotechnologie GmbH
  • Pace Analytical Services, LLC
  • Promega Corporation
  • QIAGEN NV
  • QPS Holdings LLC
  • Samsung Biologics Co., Ltd.
  • SGS SA
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Toxikon Corporation
  • WuXi AppTec Co., Ltd.
Product Code: MRR-437D4595795B

The Biologics Safety Testing Market was valued at USD 7.30 billion in 2025 and is projected to grow to USD 8.29 billion in 2026, with a CAGR of 15.41%, reaching USD 19.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.30 billion
Estimated Year [2026] USD 8.29 billion
Forecast Year [2032] USD 19.92 billion
CAGR (%) 15.41%

A strategic primer on biologics safety testing priorities, regulatory expectations, and operational implications for laboratories and manufacturers

The biologics safety testing landscape demands a disciplined synthesis of scientific rigor, regulatory awareness, and operational pragmatism. Laboratories, contract research organizations, and biologics developers must align testing strategies with evolving expectations for product quality, patient safety, and supply chain resilience. This introduction frames the essential dimensions stakeholders must consider when prioritizing investments in assay platforms, validation workflows, and data integrity practices.

Across discovery, preclinical development, and manufacturing, biologics safety testing functions as a risk-control mechanism that prevents contamination, verifies identity, and ensures product consistency. The contemporary environment adds layers of complexity: novel modalities such as gene and cell therapies require bespoke assays; accelerated development timelines place heightened emphasis on rapid, scientifically defensible testing; and the global regulatory community is converging on more detailed expectations for characterization and release testing. Consequently, teams must balance speed with robustness, integrating orthogonal methods and risk-based testing plans to meet both scientific and regulatory endpoints.

This section establishes the context for the ensuing analysis by emphasizing the interplay between technological capability, regulatory evolution, and operational execution. It prepares readers to interpret subsequent sections that examine shifting market dynamics, tariff impacts, segmentation nuances, regional differentiators, competitive positioning, and recommended actions to strengthen biologics safety testing programs.

How technological innovation, regulatory harmonization, and evolving service models are reshaping biologics safety testing practices and operational priorities

The landscape of biologics safety testing is undergoing transformative shifts driven by advances in modality diversity, analytical technology, and regulatory focus. Emerging modalities such as viral vector-based gene therapies and cell therapies have introduced new analytical endpoints and validation challenges, prompting laboratories to expand technical capabilities and invest in orthogonal assay development. Simultaneously, next-generation sequencing, digital PCR, and high-sensitivity immunoassays are enabling earlier and more precise detection of contaminants and impurities, which improves risk mitigation but requires heightened expertise and quality systems.

Regulatory bodies are increasingly emphasizing science-based justification for testing strategies, data traceability, and enhanced characterization of critical quality attributes. This trend elevates the importance of method validation, cross-platform comparability, and comprehensive documentation. As regulators harmonize expectations for biologics safety across jurisdictions, organizations must create adaptable testing frameworks that can accommodate regional nuances without duplicating effort. In parallel, the drive for faster development timelines and supply chain continuity is accelerating adoption of automation and digital data management solutions that reduce operator variability and strengthen audit readiness.

Operationally, there is a shift towards integrated service models in which contract research organizations and specialist testing labs provide end-to-end support across assay development, validation, and routine release testing. These integrated models offer scale, specialized expertise, and economies in equipment utilization, but they also require transparent quality agreements and aligned communication protocols to ensure consistent testing outcomes. In essence, technological innovation, evolving regulation, and shifting service delivery models are collectively reshaping how organizations approach biologics safety testing, compelling leaders to re-evaluate capability roadmaps and partnerships to remain compliant and competitive.

Supply chain resilience strategies and procurement realignment prompted by tariff adjustments that affect biologics testing equipment, reagents, and service continuity

In 2025, tariff adjustments have introduced practical considerations that affect procurement strategies, supply chains, and cost-structure planning for biologics safety testing stakeholders. Tariff measures have increased the emphasis on supplier diversification and onshore capability development as organizations seek to reduce exposure to cross-border trade frictions. As a result, procurement teams are reassessing long-established sourcing relationships for key instruments and critical reagents, while supply chain and quality leaders are scrutinizing alternate qualification pathways to avoid disruptions in testing continuity.

The cumulative impact of tariffs is not limited to procurement costs; it also influences capital planning and technology adoption timelines. Laboratories and manufacturers that previously relied on single-source vendors are now evaluating the feasibility of investing in domestic manufacturing or qualifying regional suppliers to preserve lead times and ensure compliance with device importation rules. Furthermore, heightened import duties have prompted some organizations to negotiate extended maintenance and spare parts agreements, or to invest in in-house servicing capabilities, thereby reducing reliance on cross-border logistics for ongoing equipment uptime.

Beyond operational adjustments, tariffs have stimulated strategic conversations about nearshoring and regional partnerships that can buffer geopolitical risk. Organizations are increasingly factoring trade policy volatility into scenario planning, contract design, and contingency inventories for critical reagents. These adaptive responses help maintain continuity of biologics safety testing programs and protect product timelines against the ripple effects of international trade policy shifts.

In-depth segmentation analysis revealing how product categories, test modalities, application domains, and end-user types drive differentiated testing priorities and capability requirements

Segment-focused insights reveal distinct drivers and decision criteria across product categories, test modalities, application domains, and end-user types. When considering product type segmentation, stakeholders evaluate the interplay between instrument performance characteristics, reagent and kit specificity, and the value proposition of services that offer method development and regulatory support. Instruments are judged on sensitivity, throughput, and adaptability to new assays; reagents and kits are assessed for lot-to-lot consistency, documentation, and scalable supply; and services are valued for technical depth, speed to result, and compliance track record.

Within the test type segmentation, priorities shift depending on analytical purpose. Adventitious agent detection requires broad-spectrum methods and comprehensive validation to ensure contaminant absence, whereas bioburden testing emphasizes routine, reproducible workflows to safeguard manufacturing lines. Cell line authentication and characterization are critical for identity assurance and stability monitoring, endotoxin testing demands precise quantitative approaches for safety assurance, mycoplasma testing necessitates sensitive detection to avoid cell-culture compromise, residual host cell protein testing focuses on robust immunoassays or orthogonal quantification methods, and sterility testing remains a cornerstone of final product release criteria. Each test type imposes distinct technical and regulatory requirements that influence laboratory staffing, equipment choice, and quality system controls.

Application-driven segmentation highlights the varied analytical complexity across therapeutic domains. Gene therapy programs require vector-specific assays and in-depth characterization of replication competence, monoclonal antibody production emphasizes aggregate and impurity profiling, recombinant protein therapeutics demand targeted impurity assays and host cell protein assessment, stem cell research focuses on identity and potency-linked assays, tissue engineering leans on sterility and scaffold compatibility testing, and vaccine development prioritizes potency and safety-related assays with large-scale lot release considerations. These application distinctions shape method validation scope, sample throughput needs, and assay lifecycle management.

Finally, end-user segmentation delineates the operational context in which testing occurs. Academic and research institutes often prioritize methodological flexibility and exploratory assay development, contract research organizations balance breadth of service with stringent turnaround commitments, and pharmaceutical and biotechnology companies integrate testing into regulated release workflows with extensive documentation and audit-readiness requirements. Understanding these segmentation layers enables stakeholders to tailor investments, partnerships, and capability roadmaps that align technical requirements with organizational objectives and compliance expectations.

Regional dynamics shaping biologics safety testing investments, regulatory compliance strategies, and capacity decisions across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a powerful influence on biologics safety testing approaches, infrastructure investments, and regulatory alignment. In the Americas, established regulatory frameworks coexist with a vibrant innovation ecosystem that supports rapid uptake of cutting-edge analytical technologies. This region places significant emphasis on method validation rigor, data integrity practices, and the integration of testing into accelerated development pathways. As a result, leaders in the Americas prioritize investments that enhance throughput, support regulatory submissions, and preserve supply chain robustness.

Across Europe, Middle East & Africa, regulatory harmonization and cross-border collaboration are shaping testing expectations and market access strategies. Laboratories in this region must navigate a mosaic of regulatory authorities while aligning to evolving guidance on characterization and release testing. Consequently, organizations emphasize interoperability of data systems, multilingual documentation, and flexible service models that can accommodate diverse national requirements. Investment decisions are often influenced by the need to demonstrate consistency across markets while managing operational complexity.

In the Asia-Pacific region, rapid expansion of biopharmaceutical manufacturing capacity and growing internal demand for advanced therapies are driving considerable activity in biologics safety testing. Here, stakeholders focus on scaling laboratory capabilities, building local reagent and consumable supply chains, and developing skilled analytical talent. Regulatory authorities in the region are increasingly issuing guidance that mirrors international standards, prompting domestic manufacturers and service providers to elevate testing practices and quality systems to compete globally. Taken together, regional considerations inform strategic choices for capacity deployment, partnership models, and compliance pathways.

How technical leadership, integrated service offerings, and strategic partnerships define competitive advantage in biologics safety testing services and solutions

Competitive positioning in biologics safety testing is defined by a blend of technical leadership, service integration, and quality assurance credentials. Leading organizations differentiate through validated platforms that offer high sensitivity and reproducibility, complemented by comprehensive documentation and accredited quality systems. Technical leadership is reinforced by investment in method development for emerging modalities and by publishing validation approaches that demonstrate scientific rigor and regulatory comprehension.

Service-oriented players distinguish themselves by providing end-to-end support that spans assay development, validation, and routine release testing, thereby reducing the coordination burden on sponsors and manufacturers. These integrated providers often offer modular engagement models that scale with client needs, from advisory support during regulatory interactions to full laboratory outsourcing for high-volume release testing. Trust in these providers is rooted in consistent delivery, transparent quality agreements, and demonstrated experience navigating complex regulatory audits.

Partnership models between instrument vendors, reagent suppliers, and testing service providers are increasingly common and serve to accelerate method adoption while ensuring reagent availability and technical support. Such collaborations can lower the barrier to entry for novel assays and help clients achieve time-sensitive goals. Finally, organizations that invest in talent development and retain specialized scientific expertise create sustainable competitive advantage, as experienced staff are critical to designing robust testing strategies and responding to atypical analytical challenges.

Actionable operational and strategic moves for leaders to enhance analytical robustness, supply chain resilience, and workforce and digital capabilities in biologics testing

Industry leaders should adopt a multifaceted action plan that balances near-term operational resilience with long-term capability development. First, prioritize investment in orthogonal testing capabilities and robust method validation frameworks to ensure analytical redundancy and regulatory defensibility. Such investments not only reduce the risk of undetected quality issues but also enhance the credibility of release decisions during regulatory inspections.

Second, strengthen supply chain resilience by qualifying multiple reagent and instrument suppliers, negotiating long-term support agreements, and developing contingency inventories for critical consumables. This proactive approach reduces vulnerability to trade disruptions and tariff-induced cost pressures while preserving testing continuity. Third, expand partnerships with specialized service providers to access niche expertise and scalable laboratory capacity without incurring prohibitive capital expenditures. Strategic outsourcing can accelerate time-to-result while enabling internal teams to focus on core development priorities.

Fourth, invest in workforce development and knowledge management to sustain technical excellence. Cross-training scientists in orthogonal methods, digital assay documentation, and regulatory science improves institutional agility. Fifth, modernize data infrastructure to support secure, auditable data capture and analytics that improve decision-making and accelerate regulatory submissions. Finally, incorporate scenario-based contingency planning that includes tariff volatility, supply chain interruptions, and rapid modality shifts so leadership teams can adapt resource allocation and operational priorities in short order.

Mixed-methods research approach combining primary interviews, technical literature synthesis, regulatory guidance review, and scenario analysis to derive actionable insights

The research methodology underpinning this analysis integrates primary interviews, technical literature review, regulatory guidance synthesis, and cross-industry benchmarking to ensure a comprehensive perspective. Primary research included structured conversations with laboratory directors, quality leaders, procurement professionals, and subject matter experts with hands-on experience in biologics analytical testing. These discussions emphasized real-world constraints, validation practice, and the operational trade-offs encountered when implementing new assays or scaling testing capacity.

Secondary research involved systematic review of peer-reviewed publications, regulatory guidance documents, and technical standards relevant to biologics safety testing. This review focused on analytical methods, validation paradigms, and evolving regulatory expectations for novel modalities. Additionally, the methodology incorporated comparative analysis of service delivery models and supplier capabilities to contextualize competitive and operational dynamics across regions.

Data synthesis prioritized triangulation, ensuring that conclusions were supported by multiple independent sources and corroborated by practitioner insights. The research also applied scenario analysis to explore the operational implications of trade policy changes, supply chain disruptions, and modality adoption timelines. Taken together, this mixed-methods approach produced evidence-based insights while preserving transparency about data sources and analytical assumptions.

Concluding synthesis that connects scientific advances, regulatory pressure, and operational resilience to define strategic priorities for biologics safety testing

Biologics safety testing sits at the intersection of scientific innovation, regulatory expectation, and operational execution, and its effective management is essential to protect patients and preserve product integrity. Across modalities, the demand for more sensitive, specific, and faster assays is reshaping laboratory investments and service delivery models. At the same time, regulatory authorities are clarifying expectations for characterization and release testing, which increases the need for rigorous validation and traceable data practices.

Operational resilience is increasingly a strategic priority, driven by supply chain uncertainties and tariff-related disruptions that compel organizations to diversify suppliers and strengthen in-region capabilities. Competitive advantage accrues to entities that can integrate technical excellence with scalable service models while maintaining audit readiness. Workforce competence, digital infrastructure, and collaborative partnerships are foundational enablers that allow organizations to adapt quickly to new technical demands and regulatory developments.

In summary, organizations that take a proactive, risk-based approach to capability development, supplier diversification, and data governance will be better positioned to navigate the evolving biologics safety testing landscape. Such preparedness not only supports compliance but also accelerates development timelines and enhances confidence in product quality across therapeutic areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Safety Testing Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Services

9. Biologics Safety Testing Market, by Test Type

  • 9.1. Adventitious Agent Detection
  • 9.2. Bioburden Testing
  • 9.3. Cell Line Authentication & Characterization
  • 9.4. Endotoxin Testing
  • 9.5. Mycoplasma Testing
  • 9.6. Residual Host Cell Protein (HCP) Testing
  • 9.7. Sterility Testing

10. Biologics Safety Testing Market, by Application

  • 10.1. Gene Therapy
  • 10.2. Monoclonal Antibody Production
  • 10.3. Recombinant Protein Therapeutics
  • 10.4. Stem Cell Research
  • 10.5. Tissue Engineering
  • 10.6. Vaccine Development

11. Biologics Safety Testing Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Biologics Safety Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biologics Safety Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biologics Safety Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biologics Safety Testing Market

16. China Biologics Safety Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Associates of Cape Cod, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Charles River Laboratories International, Inc.
  • 17.10. Clean Biologics SAS
  • 17.11. Cytiva Europe GmbH
  • 17.12. Danaher Corporation
  • 17.13. Eurofins Scientific SE
  • 17.14. FUJIFILM Corporation
  • 17.15. GenScript Biotech Corporation
  • 17.16. Intertek Group plc
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Merck KGaA
  • 17.19. Microcoat Biotechnologie GmbH
  • 17.20. Pace Analytical Services, LLC
  • 17.21. Promega Corporation
  • 17.22. QIAGEN N.V.
  • 17.23. QPS Holdings LLC
  • 17.24. Samsung Biologics Co., Ltd.
  • 17.25. SGS SA
  • 17.26. Syngene International Limited
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. Toxikon Corporation
  • 17.29. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS SAFETY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS SAFETY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ADVENTITIOUS AGENT DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ADVENTITIOUS AGENT DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ADVENTITIOUS AGENT DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CELL LINE AUTHENTICATION & CHARACTERIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CELL LINE AUTHENTICATION & CHARACTERIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CELL LINE AUTHENTICATION & CHARACTERIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MYCOPLASMA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MYCOPLASMA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MYCOPLASMA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RESIDUAL HOST CELL PROTEIN (HCP) TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RESIDUAL HOST CELL PROTEIN (HCP) TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RESIDUAL HOST CELL PROTEIN (HCP) TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STERILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STERILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STERILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RECOMBINANT PROTEIN THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY RECOMBINANT PROTEIN THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BIOLOGICS SAFETY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GCC BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. G7 BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. G7 BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NATO BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. NATO BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NATO BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA BIOLOGICS SAFETY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)